About NanOlogy

NanOlogy is a clinical-stage oncology company advancing the PurcisionTM particle engineering technology platform designed to optimize intratumoral drug therapy to improve solid tumor response and minimize the serious toxicities associated with systemic combinations.

Overview

Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained investigational drugs to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote anti-tumor immunomodulation.

Purcision Technology: Developed by CritiTech, Inc. (Lawrence, KS) and licensed to NanOlogy for oncology, the Purcision commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical fluid carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local therapeutic drug release over time with gradual systemic elimination at subtoxic levels. Feasibility of the Purcision technology has been established in multiple drug classes including taxanes, platins, TKIs, and PARPIs. Two clinical stage investigational drugs (LSAM-PTX and LSAM-DTX) have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation.

Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, to delay or prevent solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, to improve solid tumor response in combination with systemic standard of care without increasing systemic toxicity.

NanOlogy Team

David is a senior life sciences executive with more than 35 years of US and global pharmaceutical experience. Prior to NanOlogy, David was CEO of Salarius, a NASDAQ traded oncology focused biotechnology company that was located at JLabs@TMC for 5+ years.  During his career, he has built, launched and managed pharmaceutical brands, including drug delivery systems, by integrating strategy, pricing, development, clinical planning, manufacturing, branding and promotional requirements into lifecycle plans, demand realization strategies/tactics and affiliate launches. His extensive experience includes the US, EU, Asia and emerging markets. Mr. Arthur earned a BS in Chemical Engineering from North Carolina State University, a Master of Business Administration from the Duke University Fuqua School of Business, and he is a licensed Professional Engineer and Six Sigma Green Belt.

John is a seasoned medical oncologist with 20 years of experience in oncology clinical research across academia and industry. Prior to NanOlogy, he was Chief Medical Officer at Rafael Holdings from November 2023 to August 2025 and created an oncology clinical development consulting business. John was Chief Medical Officer at Oncorus from Feb 2022 to June 2023 and Senior Vice President of Clinical Development from Oct 2018 to Feb 2022. At Oncorus, he was responsible for overseeing all aspects of intratumoral development of the company’s lead asset. Prior to Oncorus, John was Senior Medical Director for H3 Biomedicine, a developer of genomics-based cancer therapies. While at H3, he supervised clinical development of H3B-8800, a first-in-human spliceosome modulator. Earlier, John held clinical roles in oncology drug development leading the pediatric oncology Phase 1 program at The University of Miami and working as Medical Director for Agenus. His immunotherapy experience includes first-in-human neoantigen vaccine, dendritic cell vaccine, GVAX, checkpoint inhibitor, and costimulatory agonist trials. John is a pediatric oncologist with 15 years of experience treating children with cancer and conducting clinical research. He conducted his pediatric hematology oncology fellowship from the Dana-Farber Cancer Institute and Children’s Hospital Boston and general pediatrics residency from The University of Rochester. John holds a Doctor of Medicine (MD) from The University of Massachusetts Medical School and Batchelor of Arts in Biological Sciences from The University of Chicago. In addition, he serves on the Medical Advisory Board of the Sarcoma Foundation of America.

Marc serves as Corporate Development Officer for NanOlogy, LLC. His current responsibilities include product and corporate development oversight. He has helped advance NanOlogy assets through preclinical and clinical research in multiple solid tumors positioning them for the next phase of clinical development and progressed collaboration opportunities with strategic and financial partners. Prior to his current role, Marc was part of DFB Pharmaceuticals, NanOlogy majority shareholder, with leadership roles in general management, operations, marketing, and business development. His leadership contributed to the growth of DFB companies from $18M to $400M, value realization of more than $2B to date, and founding of NanOlogy. Earlier in his career, he worked for Procter & Gamble, Merck, and UTMB at Galveston. Marc holds a Batchelor of Science of Pharmacy from The Ohio State University and a Master of Business Administration from The University of Texas at Austin.

 

Shelagh is VP of Clinical Development for NanOlogy. She has worked in medical product development for over 25 years on a variety of clinical programs leading to multiple FDA and European approvals. Shelagh has held senior management positions in clinical operations, with responsibility for full clinical development programs across US and Europe, and has corporate experience in pharmaceutical, device, and clinical research organization settings. She has consulted in regulatory affairs and quality assurance and has served on Safety Review Boards and Clinical and Scientific Advisory Boards for several start-up biotechnology companies. Shelagh is a member of the Association of Clinical Research Professionals, American Society of Clinical Oncology, Society for Neuro-Oncology, and Society for Quality Assurance (SQA) and is a member of the SQA Clinical Sub-Specialty group. Shelagh holds a Batchelor of Science in biological sciences at Aston University and Doctor of Philosophy (PhD) in surgical sciences at Knightsbridge University.

Holly is Director of Product Development for NanOlogy. Holly has 13 years of experience in pharmacology, toxicology, formulation development, cGMP manufacturing, and bioanalytical assay development. Holly has led IND-enabling nonclinical activities for several of NanOlogy’s oncologic indications.

Prior to NanOlogy, Holly held research and development roles at US Biotest, Fziomed, Illumina, and Rosetta Inpharmatics (a Merck subsidiary), as well as conducted research at Fred Hutchinson Cancer Research Center-Seattle, University of California-San Francisco and Cal Poly-San Luis Obispo.

Holly completed her undergraduate degree in microbiology at University of Washington.

Jacob leads formulation development, CMC, and related activities for NanOlogy.  He is also Sr. Director of Technical Operations of CritiTech Particle Engineering Solutions, responsible for leading a cross-functional team of manufacturing, analytical, and engineering professionals focused on the development and production of innovative drug products and manufacturing technologies.  Jacob was a formulation chemist for Delaval and an Adjunct Professor at Rockhurst University before joining CritiTech.  Jacob holds a Bachelor of Science in Biochemistry and Master of Business Administration from Rockhurst University.

Mike is Scientific Advisor to NanOlogy overseeing development activities related the Purcision™ technology. Mike is also Chief Scientific Officer for CritiTech, Inc. and has over 40 years of experience in the development of pharmaceutical products including leadership roles with Sandoz, Marion Laboratories and successor companies, Quintiles, Cardinal Health, and The University of Kansas, where he helped advance early-stage oncology compounds from research into clinical trials. During his career, Mike contributed to the development and launch of several new and reformulated products including Gris-PEG® tablets, Triaminic® cold medications, Tavist® syrup, Tavist-D® tablets, Mellaril® suspension and tablets, Parlodel® tablets, Zinecard® injectable solution, Cardizem QD® capsules, Anzemet® tablets and injectable solution, Allegra D® tablets, Allegra® suspension, Pentasa® capsules, Silvadene® cream, and Chlora-Prep®. Mike holds a Bachelor of Science in Chemistry & honorary PhD from Missouri Western State University and Master of Science & Doctor of Philosophy in Pharmaceutics and Pharmaceutical Chemistry from The University of Kansas.

NanOlogy Board of Managers

Paul is founder and chairman of NanOlogy and CEO of DFB Pharmaceuticals. In 1990, Paul and two partners founded DFB growing annual sales from $18 million to more than $400 million across multiple companies, with operations in Texas, New Jersey, Germany, and Canada. This growth was achieved with no shareholder dilution. DFB sold major operating companies by 2012 realizing more than $1.5 billion of value.

In 2013, Paul and a remaining partner invested some of the proceeds into a new vision for DFB. This vision leveraged a retained operating company, Phyton Biotech, to establish a foothold in oncology. This led to the identification of the innovative Purcision technology, and collaboration with CritiTech in 2015, to develop the technology under a newly created venture, NanOlogy, LLC. NanOlogy has now progressed investigational drugs based on the technology into clinical research across multiple solid tumors.

Before founding DFB, Paul had nearly two decades of executive leadership experience with Johnson & Johnson and Baxter, and owner of several industrial distribution companies culminating in successful turnarounds and divestitures. Paul serves on the board of directors of Renaissance Acquisition Holdings LLC, Multicultural Alliance, and RXi Pharmaceuticals Corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University.

Mark leads legal and regulatory affairs for NanOlogy. Mark is also Chief Legal Officer and a Managing Director of DFB and has over 25 years of experience as an executive in the pharmaceutical industry. In addition to serving as DFB’s General Counsel, Mark is on the DFB and Phyton Biotech Executive Committees.

As outside counsel, Mark joined the DFB board of directors in 1990, and joined DFB as its Chief Legal Officer in 1993. He has also established and led Quality, Regulatory Affairs and Compliance functions across multiple pharmaceutical businesses in the DFB family of companies. Prior to joining DFB, Mark spent twelve years as a corporate lawyer in private practice. He currently serves on the board of DFB Pharmaceuticals LLC and TableTop Media LLC. Mark holds a Bachelor of Business Administration from Texas A&M University and a Juris Doctor in Law from Southern Methodist University.

Maxwell leads finance and corporate development for NanOlogy. Maxwell is also a Managing Director of DFB. He is part of a team that manages DFB’s business interests in pharmaceutical manufacturing and product development. Maxwell serves on the DFB and Phyton Biotech Executive Committees and plays a lead role in developing, evaluating, structuring, and executing new business and investment opportunities.

Prior to his current role, Maxwell was Vice President of Corporate Development for DFB, where he led strategic planning, acquisition and growth initiatives across multiple life science and medical technology businesses. For four years prior to its sale, he was a member of the senior management team of Healthpoint Biotherapeutics, leading business development and international sales and marketing. He initially joined DFB as Director of Corporate Finance with responsibility for capital raising and financial planning and analysis for DFB and its portfolio of companies.

Before joining DFB, Maxwell was an investment banker with Bank of America Securities, where he was responsible for the execution of capital raising and M&A transactions in a variety of industries. He currently serves on the boards of Renaissance Acquisition Holdings LLC, TableTop Media LLC, Bio NorthTX, and Trinity Valley School.

Maxwell holds a Bachelor of Arts degree from Vanderbilt University, and a Master of Business Administration from The Fuqua School of Business at Duke University.

Marc leads product and business development for NanOlogy. Marc is also a Managing Director of DFB and is part of a small talented team responsible for identifying new healthcare investment opportunities and leading them through development to value creation. Marc helped establish NanOlogy in 2015 to advance tumor-directed drug therapy. Prior to his current role, Marc led the transformation of Phyton Biotech, a company wholly owned and operated by DFB, to a standalone commercial API business.

Marc has been with DFB since 1993 with leadership roles in business development, marketing, project management, and operations across the DFB family of companies. Earlier in his career, Marc worked for Procter & Gamble as a market analyst, Merck as a pharmaceutical representative, and as a clinical pharmacist in Ohio and Texas.

A graduate of the Ohio State University with a Bachelor of Science in Clinical Pharmacy, Marc received his Master of Business Administration from the University of Texas at Austin.

Sam is Chairman of CritiTech and has been with CritiTech in leadership roles since 2003 and serves on the board of NanOlogy. He played an integral role in establishing and advancing CritiTech’s Purcision technology, which now forms the basis for the NanOlogy drug platform.

Sam has been involved in funding and development of early-stage life science and technology companies for over three decades. He has been extensively involved in supporting life science and technology commercialization and has held a variety of roles with the Kansas Technology Enterprise Corporation (KTEC). KTEC is now managed by the Kansas Board of Regents through the Kansas Epscore program, and Sam continues to serve on the advisory committee. In addition, Sam has held leadership roles with the Kansas University Center for Research and is currently a member of the Board of Trustees. Sam is also President of TerraMetrics Agriculture, Inc., a satellite remote sensing company with several applications in the agriculture industry.

Upon earning a Master of Business Administration, Sam entered the banking business and served with several organizations beginning with First National Bank of Topeka. He returned home to join First National Bank of Lawrence and eventually Douglas County Bank. He left Douglas County Bank to establish his own investment group and was one of the founders of University National Bank where he still serves on the board of directors.

Matthew is the president of CritiTech, Inc. where he is responsible for leading corporate strategy, strategic partnerships, and business operations and serves on the board of NanOlogy. He has nearly two decades of executive leadership and investment management experience with early-stage life sciences companies. Start-up technology companies with whom Matthew has worked for or assisted have raised over $200,000,000 in private equity capital. Under his guidance, CritiTech has successfully utilized its Purcison Technology to develop numerous drugs, including the oncology drugs being developed by NanOlogy. Matthew also serves as the president of CritiTech Particle Engineering Solutions, a pharmaceutical contract development and manufacturing organization, customers of which include “Top 15” pharmaceutical companies. Matthew started his professional career as a senior consultant with Deloitte Consulting, where he provided strategy and information technology consulting services to Fortune 1000 companies.

Matthew serves on the boards of CritiTech, CritiTech Particle Engineering Solutions, and NanOlogy. He also serves on the board of Truity Credit Union, founded in 1939, that now serves over 69,000 members and manages more than $800 million in assets. Phillips 66, Conoco Phillips, and Tyson Foods are among the many Select Employee Groups served by Truity.

Matthew received a Juris Doctor in Law and Master of Business Administration from the University of Kansas and a Bachelor of Business Administration (summa cum laude) from Benedictine College.

Gere leads medical affairs for NanOlogy. Gere is also CEO and Chairman of US Biotest, and played a key role in establishing the collaboration with CritiTech and DFB to form NanOlogy. He, and his team, are responsible for medical and regulatory affairs, preclinical research, and early clinical trial research for NanOlogy.

Gere’s aptitude for drug development was demonstrated while a professor at the University of Southern California, where his research received funding from the NIH, Department of Defense, National Science Foundation, and BARDA. This work led to the elucidation of the renin-angiotensin system in epithelial tissue repair and preovulatory follicle development in the ovary. Projects initiated at the discovery level in Gere’s laboratory at USC were advanced to US Biotest, a drug development company he founded to support regulatory activities and perform clinical trials.

Gere has since contributed to development and regulatory approval of many products sold worldwide, and has collaborated with several “big pharma” companies in creating successful products. He has been recognized for this work by many professional societies in the United States and around the world.

Gere graduated from the University of Kansas, majoring in comparative physiology and cell biology. He received his Doctor of Medicine from Baylor College of Medicine, completed his residency at Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, and completed his fellowship at NIH and Walter Reed Army Medical Hospital.